- Home
- SFL vs MESO Comparison
SFL vs MESO Comparison
Compare SFL & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- MESO
- Stock Information
- Founded
- SFL 2003
- MESO 2004
- Country
- SFL Bermuda
- MESO Australia
- Employees
- SFL N/A
- MESO N/A
- Industry
- SFL Marine Transportation
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SFL Consumer Discretionary
- MESO Health Care
- Exchange
- SFL Nasdaq
- MESO Nasdaq
- Market Cap
- SFL 1.5B
- MESO 1.7B
- IPO Year
- SFL N/A
- MESO N/A
- Fundamental
- Price
- SFL $8.20
- MESO $12.48
- Analyst Decision
- SFL Strong Buy
- MESO Buy
- Analyst Count
- SFL 2
- MESO 4
- Target Price
- SFL $14.50
- MESO $18.00
- AVG Volume (30 Days)
- SFL 1.5M
- MESO 305.9K
- Earning Date
- SFL 05-13-2025
- MESO 02-26-2025
- Dividend Yield
- SFL 13.18%
- MESO N/A
- EPS Growth
- SFL 52.99
- MESO N/A
- EPS
- SFL 1.01
- MESO N/A
- Revenue
- SFL $894,061,000.00
- MESO $5,670,000.00
- Revenue This Year
- SFL N/A
- MESO $228.57
- Revenue Next Year
- SFL $5.49
- MESO $356.77
- P/E Ratio
- SFL $8.07
- MESO N/A
- Revenue Growth
- SFL 20.12
- MESO N/A
- 52 Week Low
- SFL $8.04
- MESO $4.60
- 52 Week High
- SFL $14.62
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- SFL 34.33
- MESO 34.58
- Support Level
- SFL $8.13
- MESO $13.60
- Resistance Level
- SFL $8.36
- MESO $14.45
- Average True Range (ATR)
- SFL 0.25
- MESO 0.49
- MACD
- SFL 0.04
- MESO 0.02
- Stochastic Oscillator
- SFL 29.09
- MESO 23.50
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship owning and chartering company. The company is engaged primarily in the ownership and operation of vessels and offshore related assets and is also involved in the charter, purchase, and sale of assets. Its oil tankers, chemical tankers, and oil product tankers are all double-hull vessels.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.